Clinical trial NCT00053833 (phase 2, status: terminated)
Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: irinotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or pathologically confirmed ovarian epithelial, primary peritoneal, or
             fallopian tube cancer

               -  No mixed mullerian and borderline ovarian tumors

          -  Surgically staged as stage III or IV at initial diagnosis

          -  Must meet one of the following criteria for refractory/relapsed disease:

               -  Relapsed within 6 months after completing front-line concurrent or sequential
                  platinum (either cisplatin or carboplatin) and taxane (paclitaxel or docetaxel)
                  chemotherapy

               -  Had a best response of increasing disease during this front-line regimen

                    -  Consolidation chemotherapy and reinduction therapy are counted as part of
                       the front-line regimen

          -  Unidimensionally measurable disease

               -  At least 2 cm by medical photograph (skin or oral lesion), palpation, plain
                  x-ray, CT scan, MRI, or other conventional technique (bone lesions not included)

               -  At least 1 cm by spiral CT scan

               -  Measurable disease must remain outside of radiotherapy field

          -  If the tumor is known to be KIT (CD117) or PDGFR positive, patient must be offered
             SWOG-S0211 if available

        PATIENT CHARACTERISTICS:

        Age

          -  Not specified

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  No angina pectoris

          -  No uncontrolled congestive heart failure

          -  No uncontrolled cardiac arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years except for the following:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Carcinoma in situ of the cervix

               -  Adequately treated stage I or II cancer from which the patient is currently in
                  complete remission

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No more than 1 prior biological response modifier

          -  At least 28 days since prior biological response modifier and recovered

        Chemotherapy

          -  See Disease Characteristics

          -  No prior topotecan or other topoisomerase I inhibitor

          -  One other additional prior chemotherapy regimen allowed

          -  At least 28 days since prior chemotherapy (14 days for weekly chemotherapy) and
             recovered

        Endocrine therapy

          -  Prior hormonal therapy allowed

          -  No concurrent hormonal therapy

        Radiotherapy

          -  At least 28 days since prior radiotherapy and recovered

          -  No prior radiotherapy to more than 25% of bone marrow

          -  No concurrent palliative radiotherapy

        Surgery

          -  At least 14 days since prior major surgery and recovered

        Other

          -  At least 28 days since prior investigational drugs and recovered

          -  No other concurrent antitumor therapy